Navigation Links
Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Date:2/5/2009

clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
2. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
3. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
4. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
5. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
6. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
8. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
9. Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
10. Leading Immunologists Convene in Boston
11. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Corporation (NASDAQ: THOR ), a world leader in mechanical ... announced today that Marta Antonucci has joined Thoratec ... This new Europe -based position is responsible ... America , including Europe , ... , and reports directly to the Chief Executive Officer. Following the ...
(Date:5/1/2015)... 1, 2015  CytRx Corporation (CYTR), a biopharmaceutical ... reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical ... in the early months of 2015, including the ... of aldoxorubicin in patients with soft tissue sarcoma, ...
(Date:5/1/2015)... The Institute for Healthcare Advancement (IHA) is ... The IHA Health Literacy Awards aim to encourage, recognize ... practice of educating or empowering organizations to deliver clear ... three categories: innovative programs, published materials and research. This ... In the area of innovative programs, the ...
Breaking Medicine Technology:Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Institute for Healthcare Advancement Announces 2015 Award Winners 2
... SYDNEY, May 23, 2011 Starpharma Holdings Limited (ASX: ... major phase 2 clinical study that demonstrated efficacy of ... Key Points: VivaGel(R) ... BV VivaGel(R) expected to avoid many shortcomings of ...
... Advanced Life Sciences Holdings, Inc. ... its Annual Meeting of Shareholders, which was previously scheduled ... (Logo:   http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) ... Sciences is a biopharmaceutical company engaged in the discovery, ...
Cached Medicine Technology:VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 2VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 3VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 4VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 5
(Date:5/1/2015)... Caicos Islands, BWI (PRWEB) May 02, 2015 ... website! It is http://www.thevenetiangracebay.com , and it ... it incorporates the stunning white and attractive turquoise hues ... study of Google, sixty seven percent of leisure travelers ... study showed that smartphones were used in the planning ...
(Date:5/1/2015)... 2015 Jusuru International has been awarded ... repositioning of its flagship nutritional supplement, Liquid BioCell™ Life, ... new name, new logo, new packaging, new products, and ... designed to identify and promote programs that serve as ... “DSA congratulates Jusuru International for their outstanding accomplishments and ...
(Date:5/1/2015)... The Workgroup for Electronic Data Interchange ... use of health IT to create efficiencies in healthcare ... the United States Government Accountability Office (GAO) for a ... Medicare. The report, “ Potential Uses of Electronically Readable ... the public on Apr. 24, 2015 and examines the ...
(Date:5/1/2015)... 01, 2015 It’s raining bills on Capitol ... proposals to expand federal support for telemedicine. , ... has been working with Congress,” said Jonathan Linkous, CEO of ... the nation is poised to embrace the use of telecommunications ... step in fulfilling ATA’s mission to improve quality, access, equity ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
Breaking Medicine News(10 mins):Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... research shows , , FRIDAY, June 13 (HealthDay News) -- ... the morning may help ease some stresses you might ... rats inhaled the aroma of roasted coffee beans, a ... proteins with healthful antioxidant activity, the researchers reported. ...
... Md., June 13 EntreMed, Inc.,(Nasdaq: ... for the treatment of cancer and inflammatory ... and Chief Executive Officer,will present a Company ... Industry Organization 2008 Annual International Convention,being held ...
... blames traffic-related pollution for increasing the risk of allergy and ... more, the closer children live to roads, the higher their ... are likely to be exposed not only to a higher ... more freshly emitted aerosols which may be more toxic," wrote ...
... the most commonly ... June 13 Roche announced today that,its new test ... allowing it to be sold for clinical use in ... approach to help ensure,reliability of test results even when ...
... Arthritis is the Leading Cause of Work Disability ... data announced today,showed that treating patients with early, ... methotrexate (MTX) resulted in an,indirect cost savings of ... the time of the study) per patient per ...
... Lower Manhattan, the terrorist attacks of September 11, 2001, ... the Health Department,s World Trade Center Health Registry, show ... posttraumatic stress disorder (PTSD) two to three years after ... developed PTSD at three times the usual rate in ...
Cached Medicine News:Health News:Coffee Beans May Be Newest Stress-Buster 2Health News:Coffee Beans May Be Newest Stress-Buster 3Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:Road pollution blamed for higher allergy risk in kids 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 4Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 5Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 6Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 7Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: